SURUNKALI GLOMERULONEFRIT KASALLIGIDA TUBULOINTERSTITSIAL FIBROZ RIVOJLANISHIDA METALLOPROTEINAZALARNING AHAMIYATI.
Article Sidebar
Main Article Content
Аннотация:
Surunkali glomerulonefritda (SGN) tubulointerstitsial fibroz rivojlanishi bu kasallikning og‘irlashgan bosqichlarida ko‘p uchraydigan patologik jarayonlardan biridir. Bu holat buyrak to‘qimalarida (asosan naychalar va ularni o‘rab turgan interstitsial to‘qima) yallig‘lanish va keyinchalik biriktiruvchi to‘qimaning ortiqcha o‘sishi (fibroz) bilan xarakterlanadi. Fibroz jarayonida normal parenxima to‘qimasi o‘rnini ortiqcha ekstrasellulyar matriks (ECM) komponentlari, jumladan kollagen, fibronektin va laminin egallaydi [2].
Article Details
Как цитировать:
Библиографические ссылки:
Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. *J Immunol.* 2001;157(2):506–512.
Zeisberg M, Khurana M. Role of epithelial-to-mesenchymal transition in renal fibrosis. *J Mol Med.* 2006;84(8):556–567.
Zhou D, Tan RJ, Lin L, Zhou L, Liu Y. Activation of Wnt/β-catenin signaling in renal fibrosis: a novel therapeutic target. *Kidney Int.* 2010;80(6):593–603.
Eddy AA. Progression in chronic kidney disease. *Adv Chronic Kidney Dis.* 2011;18(4):271–275.
Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. *Endocrine.* 2009;35(1):1–10.
Liu Y, Wang J, Ni Z. Matrix metalloproteinases and tissue inhibitors of metalloproteinases expression in patients with chronic kidney disease. *Ren Fail.* 2014;36(8):1231–1237.
Ho J, Wiebe C, Gibson IW, Rush DN, Nickerson PW. Immune monitoring of kidney allografts. *Am J Kidney Dis.* 2010;55(3):360–373.
Yoshida T, Kurella Tamura M, Ubara Y, Hoshino J. Pathophysiology and management of fibrotic kidney disease. *Nephrol Dial Transplant.* 2013;28(3):505–512.
Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. *Circ Res.* 2001;75(3):539–545.
Liu Y. Cellular and molecular mechanisms of renal fibrosis. *Nat Rev Nephrol.* 2011;7(12):684–696.
Genovese F, Manresa AA, Leeming DJ, Karsdal MA, Boor P. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? *Fibrogenesis Tissue Repair.* 2014;7(4):1–14.
Tan RJ, Zhou D, Liu Y. Signaling crosstalk between tubular epithelial cells and interstitial fibroblasts after kidney injury. *Kidney Int.* 2016;90(6):1189–1198.
Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circ Res.* 2003;92(8):827–839.
Guo JK, Cantley LG. Cellular maintenance and repair of the kidney. *Annu Rev Physiol.* 2010;72:357–376.
Boor P, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. *Nat Rev Nephrol.* 2011;7(12):684–696.
Liu N, Guo JK, Pang M, Tolbert E, Ponnusamy M, Gong R, et al. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. *J Am Soc Nephrol.* 2012;23(5):854–867.
Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy ZA. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? *Clin J Am Soc Nephrol.* 2008;3(2):505–521.
LeBleu VS, Taduri G, O’Connell J, Teng Y, Cooke VG, Woda C, et al. Origin and function of myofibroblasts in kidney fibrosis. *Nat Med.* 2013;19(8):1047–1053.
Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. *Am J Physiol Renal Physiol.* 2012;302(11):F1351–F1361.
Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA. Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect. *Kidney Int.* 2004;66(5):1774–1784.
Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. *Nat Rev Nephrol.* 2020;16(5):269–288.
Karsdal MA, Daniels SJ, Holm Nielsen S, Bager CL, Rasmussen DGK, Loeys B, et al. Collagen biology and non-invasive biomarkers of liver fibrosis. *Liver Int.* 2020;40(4):736–750. (Buyrak fibrozida ECM biomarkerlar bilan solishtiruv uchun ham qo‘llaniladi).
Leung JC, Chan LY, Tam KY, Tang SC, Lam MF, Lai KN. Regulation of tubular epithelial cell-induced myofibroblast activation by MMP-2 and MMP-9. *Kidney Int.* 2005;67(2):560–573.
Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. *J Am Soc Nephrol.* 2010;21(2):212–222.
Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. *Nat Rev Nephrol.* 2015;11(5):264–276.